

Squamous cell carcinoma of the thyroid gland: primary or secondary disease?

M I SYED¹, M STEWART², S SYED³, S DAHILL⁴, C ADAMS⁵, D R MCLELLAN³,
L J CLARK¹

¹Department of Otolaryngology and Head and Neck Surgery, ³Department of Histopathology, Southern General Hospital, Greater Glasgow and Clyde NHS Trust, Glasgow, ²Departments of Otolaryngology and Head and Neck Surgery, ⁴Department of Histopathology, and ⁵Department of Radiology, Royal Alexandra Hospital, Greater Glasgow and Clyde NHS Trust, Paisley, Scotland, UK

Abstract

Objective: To review the aetiopathogenesis, clinical characteristics, immunohistochemical profile, prognosis and treatment options for primary thyroid squamous cell carcinoma, and to compare it with squamous cell carcinoma metastatic to the thyroid, thus providing the reader with a framework for differentiating primary and secondary disease.

Method: Review of English language literature from the past 25 years.

Search strategy: A search of the Medline, Embase and Cochrane databases (April 1984 to April 2009) was undertaken to enable a comprehensive review.

Results: After applying strict criteria for the diagnosis of primary thyroid squamous cell carcinoma, 28 articles were identified reporting 84 cases. When reviewing secondary thyroid squamous cell carcinoma, we only analysed cases of squamous cell carcinoma metastatic to the thyroid gland, and found 28 articles reporting 78 cases.

Conclusion: It is possible to differentiate between primary and secondary thyroid squamous cell carcinoma, on the basis of combined evidence from clinical examination and endoscopic, pathological and radiological evaluation. Such differentiation is important, as the prognosis for primary squamous cell carcinoma is uniformly poor irrespective of treatment, and the most suitable option may be supportive therapy. Treatment for secondary squamous cell carcinoma of the thyroid varies with the site and extent of spread of the primary tumour.

Key words: Thyroid Neoplasms; Tumour Metastasis; Squamous Carcinoma

Introduction

By definition, ‘squamous cell carcinoma of [the] thyroid should be composed entirely of tumour cells with squamous differentiation’.¹ This definition gains importance when one considers that up to 43 per cent of papillary carcinomas will contain regions of squamous cell metaplasia, and that many anaplastic carcinomas will be composed, in part, of squamoid regions.² Additionally, adenosquamous cell carcinomas have a squamous element.

Squamous cell carcinoma (SCC) of the thyroid gland is a rare entity. It can represent either primary SCC of the thyroid gland itself or secondary involvement of the gland, due to either extension of SCC from an adjacent structure or metastasis from a distant SCC. Direct extension and metastatic involvement of the thyroid gland are more common than generally realised, occurring approximately 10 times more frequently than primary thyroid SCC.³

Primary SCC of the thyroid constitutes less than 1 per cent of all primary thyroid carcinomas.⁴ Sporadic cases have been reported in literature, with most being derived from autopsy studies.

Advanced primary carcinomas of adjacent structures such as the tongue base, larynx, pharynx or upper oesophagus can directly invade the thyroid gland, and the gland may be the seat of metastases from SCC of the lung, head, neck or gastrointestinal tract. Despite its rich vasculature, the incidence of metastasis in the thyroid gland is low and accounts for only 2–3 per cent of all malignant tumours of the thyroid gland,⁵ of which SCC forms only a small fraction.

Materials and methods

Medical literature available in English was reviewed by searching the Pubmed, Embase and Cochrane databases using the medical subject headings ‘squamous

cell carcinoma of thyroid', 'primary squamous cell carcinoma of thyroid', 'secondary squamous cell carcinoma of thyroid' and 'metastases to the thyroid', for articles published in the last 25 years (April 1984 to April 2009).

When reviewing secondary thyroid SCC, we analysed only those cases of SCC metastatic to the thyroid gland: we excluded cases of thyroid SCC which had spread from adjacent structures (e.g. tongue base, larynx, pharynx and proximal oesophagus).

The literature on metastatic involvement of the thyroid gland by SCC is difficult to analyse and compare for many reasons. We could identify no other studies specifically addressing metastasis of SCC to the thyroid gland. Most studies have analysed metastasis to the thyroid gland from a heterogeneous group of cancers. Therefore, comments from these studies regarding prognosis and management cannot be specifically applied to metastasis of SCC to the thyroid gland.

In addition, many reports are based on autopsy studies, and the unavailability of immunohistochemical analysis in earlier times makes some of the diagnoses of this era questionable.

We excluded from this review the following cases: those in which the diagnosis was based only on fine needle aspiration cytology (FNAC), without immunohistochemical analysis; those in which computed tomography (CT) scanning or autopsy were not done to exclude a primary;⁶ and those in which SCC was present in association with other thyroid malignancies such as papillary carcinoma,^{7,8} adenocarcinoma⁶ or anaplastic carcinoma.²

Results

Applying the above criteria, we identified 28 case reports or case series, reporting a total of 84 cases of primary SCC of the thyroid gland occurring over the last 25 years. We analysed the treatment modalities and survival time (in months) for each of these patients, as outlined in Table I.

Table II lists the literature on metastasis to the thyroid gland published over the last 25 years (28 articles reporting 78 cases). In this table, we have attempted to separate out cases of SCC metastases to the thyroid gland, and to list their primary site(s). The lung was found to be the commonest primary site.

Discussion

Aetiopathogenesis

Primary SCC of the thyroid gland is an extremely rare neoplasm, representing less than 1 per cent of all primary thyroid malignancies.⁴

The thyroid gland does not normally contain squamous epithelium; therefore, the origin of primary SCC within the thyroid remains controversial. Several

hypotheses have been proposed, but every theory has been disputed.

One of the earliest theories was proposed by Goldberg and Harvey,⁶³ who believed that squamous cells were derived from the embryonic remnants of the thyroglossal duct. In early embryonic life, the thyroid gland migrates downwards, and a duct may persist lined by squamous, columnar or transitional epithelium. Normally, this duct completely involutes, but if it persists it may be the source of a thyroglossal cyst or epidermoidal carcinoma. This theory has been challenged by many. The lowest part of the thyroglossal duct forms the pyramidal lobe of the thyroid gland, and if these squamous cells were to give rise to malignancy then SCC would be expected to arise in the pyramidal lobe of the thyroid gland. However, clinically, most of the reported cases of primary SCC of the thyroid originate in the lateral lobe(s).

Branchial arch remnants (e.g. the ultimobranchial body and thymic epithelium) have also been suggested as sources of squamous epithelium,³ but these theories remain largely unproven.

A recent theory proposed that the cell of origin of pure SCC arises due to squamous metaplasia.¹⁹ However, this appears unconvincing since the clinical conditions associated with squamous metaplasia (e.g. Hashimoto's thyroiditis) are rarely associated with primary SCC; the reviewed literature contained only three reported cases of primary SCC of the thyroid arising in association with chronic thyroiditis.^{4,26,64} Secondary involvement of the thyroid gland by SCC is far more common, and can occur by direct local invasion from tumours in adjacent structures (e.g. the larynx, pharynx, proximal oesophagus, trachea, soft tissues or mediastinum), or from metastases from other sites giving rise to primary SCC (e.g. the lung, head, neck and gastrointestinal tract). Amongst SCCs of the head and neck, laryngeal and pharyngeal SCCs seem to have the greatest tendency to invade the thyroid by direct extension.⁶⁵

Gulisano *et al.*⁶⁶ attempted to find the route of metastatic spread to the thyroid gland. In three patients with pharyngeal SCC, they injected methylene blue into the submucosa of the pyriform sinus, before commencing the surgical procedure, which included hemithyroidectomy. The superior portion of the thyroid lobe stained, from which they concluded that tumour cells tend to follow periarterial lymphatic vessels.

Clinical features

Clinically, primary thyroid SCC is very aggressive; in this respect, it resembles anaplastic thyroid carcinoma.⁶ Patients typically present with a rapidly increasing neck mass invading the strap muscles, soft tissues and blood vessels of the neck, compressing the trachea and oesophagus, and having accompanying cervical lymphadenopathy. Dysphagia, dyspnoea, hoarseness and neck pain typically ensue. In contrast to primary thyroid SCC, secondary invasion of the thyroid gland from adjacent

TABLE I
PRIMARY THYROID SCC TREATMENT AND SURVIVAL: 25-YEAR REVIEW

Study	Year	Cases (n)	Treatment [†]	Med survival (mth)
Long <i>et al.</i> ⁹	2009	1	Surg + RT + CT	12 [†]
Makay <i>et al.</i> ¹⁰	2008	3	Surg + RT + CT	<5
Müssig <i>et al.</i> ¹¹	2008	1	Surg	Unknown
Fassan <i>et al.</i> ¹²	2007	1	Surg	Unknown
Ab Hadi <i>et al.</i> ¹³	2007	1	RT	Unknown
Chintamani <i>et al.</i> ¹⁴	2007	3	Surg + RT	12
Booya <i>et al.</i> ¹⁵	2006	10	Surg (8) Adj RT (10) Adj CT (4)	8.6
Sanchez-Sosa <i>et al.</i> ¹⁶	2006	1	Surg	Unknown
Zimmer <i>et al.</i> ¹⁷	2003	1	Surg	7
Zhou ¹⁸	2002	4	Adj RT + CT Surg (4) Adj RT (2) Adj CT (1)	6
Sahoo <i>et al.</i> ¹⁹	2002	2	Surg	4.5
Lam <i>et al.</i> ²⁰	2001	4	Surg (3) No treatment (1)	4
Agrawal <i>et al.</i> ²¹	2001	1	Surg Adj RT	Unknown
Jones <i>et al.</i> ²²	2000	1	Surg	8
Cook <i>et al.</i> ²³	1999	16	Surg (2) RT (8) Surg + RT (5) RT + CT (1)	16
Kumar <i>et al.</i> ²⁴	1999	2	Surg (1) No treatment (1)	11
Wan Muhaizan <i>et al.</i> ²⁵	1998	1	Surg + RT	24 [†]
Chaudhary <i>et al.</i> ²⁶	1994	1	Surg Adj RT	<12
Theander <i>et al.</i> ²⁷	1993	1	Surg Adj RT + CT	7
Tsuchiya <i>et al.</i> ²⁸	1990	3	Surg	5
Harada <i>et al.</i> ²⁹	1989	2	Surg + RT	9
Korovin <i>et al.</i> ⁴	1989	4	Surg + RT + CT (3) Surg + RT (1)	8.5
Simpson & Carruthers ³⁰	1988	8	Surg + RT (4) Surg + RT + CT (1) Surg (1) RT + CT (2)	5
Sarda <i>et al.</i> ³¹	1988	8	Surg + RT + CT	6
Misonou <i>et al.</i> ³²	1988	1	Surg Adj RT + CT	6
Riddle & Dincsoy ³³	1987	1	No treatment	3
Huang & Lin ³⁴	1986	1	Surg	Unknown
Kapoor <i>et al.</i> ³⁵	1985	1	Surg	Unknown

*Where primary treatment differed amongst a group of patients, numbers undergoing each treatment type are given in parentheses. †One or more patients still alive at time of writing. SCC = squamous cell carcinoma; med = median; mth = months; surg = surgery; RT = radiotherapy; CT = chemotherapy; adj = adjuvant

structures such as the larynx or tongue base is usually discovered at surgery, and confirmed by histological examination.⁶⁵ Occasionally, the presentation may be that of a neck mass, as sometimes seen in cases of proximal oesophageal SCC extending to the thyroid gland.

The clinical presentation of SCC metastases to the thyroid gland can be variable, depending largely on the extent of the primary tumour.

Lam and Lo⁵³ studied a series of patients with metastases to the thyroid; five of these cases were SCC, only one of which presented with an enlarging neck mass, the rest being discovered at autopsy. In contrast, Papi and colleagues⁴⁰ case series included 11 primary thyroid SCC cases, seven of which presented clinically as a thyroid nodule.

Diagnosis

The diagnosis of thyroid SCC involves a combination of clinical examination plus endoscopic, pathological and radiological evaluation.

It is vital to exclude secondary involvement of the thyroid, from primary SCC in adjacent structures and from metastasis from the head, neck, chest, upper digestive tract and pelvis, before making a diagnosis of primary thyroid SCC.

Endoscopy

Panendoscopy should be performed to exclude a primary lesion in the nasopharynx, oropharynx, hypopharynx, larynx, oesophagus or bronchus.

TABLE II
METASTASES TO THE THYROID GLAND: 25-YEAR REVIEW

Study	Year	Cases (n)	SCC cases (n)	Primary site(s)*	Med survival (mth)
Jankowska <i>et al.</i> ³⁶	2008	3	2	Tongue, tonsil	182 [†]
Lee <i>et al.</i> ³⁷	2007	4	1	Lung	Unknown
Ciobanu <i>et al.</i> ³⁸	2007	16	7	Lung, larynx	Unknown
Iesalnieks <i>et al.</i> ³⁹	2007	8	—	—	—
Papi <i>et al.</i> ⁴⁰	2007	32	11	Lung, oesophagus, larynx	33
Bandyopadhyay <i>et al.</i> ⁴¹	2006	1	1	Lung	8
Karapanagiotou <i>et al.</i> ⁴²	2006	1	1	Cervix	12
Cichoń <i>et al.</i> ⁵	2006	17	—	—	—
Gerges <i>et al.</i> ⁴³	2006	7	—	—	—
Preuss <i>et al.</i> ⁴⁴	2005	1	1	Lung	12 [†]
Mirallié <i>et al.</i> ⁴⁵	2005	29	2	Lung	26 [†]
Kim <i>et al.</i> ⁴⁶	2005	22	6	Oesophagus, larynx, cervix	8 [†]
Dequanter <i>et al.</i> ⁴⁷	2004	11	7	Lung, oesophagus, oropharynx	10
Wood <i>et al.</i> ⁴⁸	2004	15	1	Bladder	24
De Ridder <i>et al.</i> ⁴⁹	2003	6	1	Head & neck	14
Schwender <i>et al.</i> ⁵⁰	2002	1	1	Oral cavity	<1
Heffess <i>et al.</i> ⁵¹	2002	36	—	—	—
Chen <i>et al.</i> ⁵²	1999	10	2	Lung, tongue	62 [†]
Lam & Lo ⁵³	1998	79	5	Lung, cervix	Unknown
Lin <i>et al.</i> ⁵⁴	1998	14	4	Lung	3.3
Nakhjavani <i>et al.</i> ⁵⁵	1997	43	2	Lung, oesophagus	16
Rosen <i>et al.</i> ⁵⁶	1995	11	3	Oral cavity, oesophagus, lung	<24
Michelow & Leiman ⁵⁷	1995	21	4	Lung, larynx	Unknown
Smith <i>et al.</i> ⁵⁸	1987	19	3	Oesophagus, lung	9
Chaco <i>et al.</i> ⁵⁹	1987	6	—	—	—
McCabe <i>et al.</i> ⁶⁰	1985	17	11	Larynx, nasopharynx, tonsil, lung, oesophagus, cervix	12
Ivy <i>et al.</i> ⁶¹	1984	30	2	Larynx	12
Vane <i>et al.</i> ⁶²	1984	8	—	—	—

*Of metastasis. [†]One or more patients still alive at time of writing. SCC = squamous cell carcinoma; med = median; mth = months

Radiology

There are no specific radiological features of thyroid SCC. Features similar to those seen in other thyroid malignancies are present. Ultrasound (US) is usually the first radiological modality used in the diagnostic investigation of a thyroid lump. The examination is simple and cost-effective, and is able to distinguish solid from cystic lesions and to define the echogenic pattern, which may suggest a benign or malignant tumour. Moreover, US-guided FNAC or core biopsy are also useful diagnostic modalities when combined with clinical and radiological findings.

Although CT is preferred, both CT and magnetic resonance imaging (MRI) scans are useful for the assessment of suspicious thyroid lumps. They allow differentiation of a thyroid mass from adjoining neck masses, and also enable assessment of the adjacent larynx and trachea to discern displacement, luminal narrowing, and vascular displacement and invasion. Evaluation should also assess calcification, cyst formation, necrosis, haemorrhage, lesion margin definition and extraglandular extension.⁶⁷

Computed tomography of the chest, abdomen and pelvis helps exclude a primary source for secondary SCC of the thyroid gland.

Primary thyroid SCC often tends to encase the oesophagus rather than invade it, leaving a fat plane between the tumour and the oesophagus, which is useful in confirming that the tumour arose from the thyroid rather than the oesophagus itself.

Metastatic disease may manifest as a solitary nodular mass or, more commonly, as multiple nodular foci; in a patient with a known primary tumour, this should raise strong suspicion of metastatic disease. In addition to CT and MRI, positron emission tomography may provide useful information enabling the identification of a primary tumour in patients with occult SCC metastases to the thyroid gland.⁶⁸

Pathology

Historical autopsy reports of primary thyroid SCC published prior to the availability of immunohistochemistry should be treated with caution. It is possible that earlier reports of primary thyroid SCC actually represent cases of secondary involvement of the thyroid from primary tumours in the trachea or oesophagus.³

By definition, 'squamous cell carcinoma of [the] thyroid should be composed entirely of tumour cells with squamous differentiation'.¹ However, half of primary thyroid SCC tumours are poorly differentiated. Although metastatic tumours generally retain the histological features of the primary tumour, they are frequently more poorly differentiated. The definition above should therefore be treated with caution. Primary thyroid SCC is also excluded if other types of thyroid carcinoma are present in close proximity.

A metastasis from another site should always be excluded before making a diagnosis of primary thyroid SCC.

Fine needle aspiration cytology is of limited value, partly due to the prevalence of poorly differentiated SCC, and partly due to the inability of FNAC to reliably distinguish between primary and metastatic SCC (although it is possible that immunocytochemistry may help clarify the diagnosis).

Macroscopically, primary thyroid SCC typically involves one or both lobes of the thyroid gland, although satellite tumour nodules have been reported. In contrast, metastases to the thyroid are most often multifocal.⁶⁹

Immunohistochemistry may be useful in distinguishing primary from metastatic thyroid SCC.

The pattern of cytokeratin expression is different in carcinomas arising from different organs, and also varies with tumour differentiation.²⁰ It has been reported that primary thyroid SCC is strongly positive for cytokeratin 19 but negative for cytokeratins 1, 4, 10/13 and 20.^{20,70} Focal positivity for cytokeratins 7 and 18 may be present in some tumours.

Occasional cases of thyroid SCC have been reported as positive for thyroglobulin, but this probably represents non-specific absorption from adjacent cells.²⁴

Thyroid transcription factor 1 expression is widely used in the diagnosis of lung and thyroid carcinomas. Thyroid transcription factor 1 is highly specific for lung and thyroid carcinoma,^{71–73} and is positive in thyroid cancers regardless of histological type.⁷⁴ It is also positive in 10⁷⁴ to 30⁷⁵ per cent of lung SCC cases.

One of our own cases (not published) was thyroid transcription factor 1 positive; primary lung carcinoma was excluded by extensive clinical and radiological assessment.

Another useful marker to be considered is calcitonin, the analysis of which enables exclusion of medullary thyroid carcinoma.

Prognosis and management

Primary thyroid SCC portends a poor prognosis regardless of therapy; secondary involvement of the thyroid, however, may be more amenable to treatment.⁴

Analysis of published survival rates for the last 25 years (Table I) shows that median survival for primary thyroid SCC is poor. Ideally, survival rates for specific tumour stages should be reported, but unfortunately most case series do not mention patients' tumour stage.

Various combinations of surgery, radiotherapy and chemotherapy have been used in the treatment of primary SCC of the thyroid.

Primary thyroid SCC extensively infiltrates and invades adjacent tissue, even when small (e.g. 1–3 cm in diameter), making surgical resection extremely difficult and frequently impossible.¹⁸

Primary thyroid SCC has been widely reported to be relatively radio-resistant, and this conclusion is well documented in the older literature.^{76–79}

Even with modern radiotherapy techniques, there has been little change in radiotherapy response rates in recent times. Sarda *et al.*³¹ reported eight patients

with primary thyroid SCC who were treated with post-operative chemoradiotherapy; seven out of these eight died of local recurrence within five months of surgery. In 2006, Booya *et al.*¹⁵ reported a series of 10 cases all of which received adjuvant radiation; these patients' median survival was 8.6 months.

The relative rarity of primary thyroid SCC makes any evaluation of chemotherapy statistically inconclusive. However, the literature indicates that chemotherapy used as an adjuvant has had disappointing results. Harada *et al.*⁸⁰ reported unimpressive responses to bleomycin and to adriamycin. Shimaoka and Tsukada⁷⁸ administered nitrogen mustard, vincristine, adriamycin and AB-132 for four cases of primary thyroid SCC, but none showed any encouraging response. Similarly, other authors^{6,15,23,30,31} have used chemotherapy for primary thyroid SCC but reported little benefit.

As with anaplastic thyroid carcinoma, primary thyroid SCC does not take up radioactive iodine, and thyroid-stimulating hormone suppression has little impact.⁸¹

Definite conclusions about the effect of chemoradiation on primary thyroid SCC cannot be drawn, due to the small number of reported cases. However, continuing modernisation in radiation techniques and advances in chemotherapy may mean that chemoradiation plays a more important role in future management of this tumour.

The cause of death in most primary thyroid SCC cases is progression of local disease, respiratory compromise, distant metastasis or treatment complications.^{17,20}

Based upon our own experience of managing primary thyroid SCC patients, and upon the fact that surgery, radiation and chemotherapy in any reported combination have little or no impact in improving outcome or prolonging survival, we recommend tracheostomy (to protect the airway, as respiratory compromise is the commonest cause of death in these patients), PEG (Percutaneous endoscopic gastrostomy) or open gastrostomy (as dysphagia from oesophageal invasion is common), and supportive treatment, rather than radical chemoradiation and surgery. The latter are by no means curative, and there is little evidence to show that they prolong life. However, there remains a limited but important role for palliative surgery, in the form of total thyroidectomy to relieve severe airway obstruction.

The management of SCC metastasis to the thyroid is poorly documented in the literature, primarily because the majority of reports are derived from pathology journals that do not comment on patient management or prognosis. In addition, the site of primary disease is so variable (including tongue, tonsil, larynx, oesophagus, cervix and bladder) that general comments about treatment cannot be made. Management depends on the site and stage of the primary tumour, the presence of other metastases, and the symptoms caused by the thyroid metastases.

We recommend that patients with treatable primary SCC should undergo total thyroidectomy for isolated metastases to the thyroid gland, not only to prolong survival but also to prevent further dissemination of the tumour (taking into account the rich blood supply of the thyroid gland, which would favour leakage of tumour emboli into the systemic circulation).⁸²

Conclusion

Squamous cell carcinoma of the thyroid gland is an uncommon condition and represents a diagnostic dilemma both for the otolaryngologist, who needs a thorough evaluation, and the pathologist. It is vital to differentiate primary and secondary involvement of the thyroid gland by SCC, as the prognosis and management of the two conditions can differ significantly.⁸²

References

- Lam KY, Sakamoto A. Squamous cell carcinoma. In: Ronald A. Delellis, Ricardo V. Lloyd, Phillip U. Heitz, Charis Eng eds. *Pathology and Genetics of Tumours of Endocrine Organs*. Lyon France: ARC press, International agency for research and cancer (IARC), 2004;81
- Kato H, Sakamoto A, Kasai N, Yagawa K. Squamous differentiation in thyroid carcinoma. With special reference to histogenesis of squamous cell carcinoma of the thyroid. *Acta Pathol Jpn* 1989;**39**:306–12
- Goldman RL. Primary squamous cell carcinoma of the thyroid gland. Report of a case and review of literature. *Am Surg* 1964;**30**:247–52
- Korovin GS, Kuriloff DB, Cho HT, Sobol SM. Squamous cell carcinoma of the thyroid: a diagnostic dilemma. *Ann Otol Rhinol Laryngol* 1989;**98**:59–65
- Cichoń S, Anielski R, Konturek A, Barczyński M, Cichoń W. Metastases to the thyroid gland: seventeen cases operated on in a single clinical center. *Langenbecks Arch Surg* 2006;**391**:581–7
- Segal K, Sidi J, Abraham A, Konichezky M, Ben-Bassat M. Pure squamous cell carcinoma and mixed adenosquamous cell carcinoma of the thyroid gland. *Head Neck Surg* 1984;**6**:1035–42
- Walvekar RR, Kane SV, D'Cruz AK. Collision tumour of the thyroid: follicular variant of papillary carcinoma and squamous carcinoma. *World J Surg Oncol* 2006;**19**:4:65
- Kleer CG, Giordano TJ, Merino MJ. Squamous cell carcinoma of the thyroid: an aggressive tumour associated with tall cell variant of papillary thyroid carcinoma. *Mod Pathol* 2000;**13**:742–6
- Long JL, Strocker AM, Wang MB, Blackwell KE. EGFR expression in primary squamous cell carcinoma of the thyroid. *Laryngoscope* 2009;**119**:89–90
- Makay O, Kaya T, Ertan Y, Icoz G, Akyildiz M, Yilmaz M *et al.* Primary squamous cell carcinoma of the thyroid: report of three cases. *Endocr J* 2008;**55**:359–64
- Müssig K, Dahm J, Koitschev A, Horger M, Müller M, Bares R *et al.* Primary squamous cell carcinoma of the thyroid. *Intern Med J* 2008;**38**:69–70
- Fassan M, Pennelli G, Pelizzo MR, Ruggie M. Primary squamous cell carcinoma of the thyroid: immunohistochemical profile and literature review. *Tumori* 2007;**93**:518–21
- Ab Hadi I, Bliss RD, Lennard TW, Welch AR. Primary squamous cell carcinoma of the thyroid gland: a case report and role of radiotherapy. *Surgeon* 2007;**5**:249–51
- Chintamani, Kulshreshtha P, Singh J, Sugandhi N, Bansal A, Bhatnagar D *et al.* Is an aggressive approach justified in the management of an aggressive cancer – the squamous cell carcinoma of thyroid? *Int Semin Surg Oncol* 2007;**27**:8
- Booya F, Sebo TJ, Kasperbauer JL, Fatourechi V. Primary squamous cell carcinoma of the thyroid: report of ten cases. *Thyroid* 2006;**16**:89–93
- Sanchez-Sosa S, Rios-Luna NP, Tamayo Bdel R, Simpson K, Albores-Saavedra J. Primary squamous cell carcinoma of the thyroid arising in Hashimoto's thyroiditis in an adolescent. *Pediatr Dev Pathol* 2006;**9**:496–500
- Zimmer PW, Wilson D, Bell N. Primary squamous cell carcinoma of the thyroid gland. *Mil Med* 2003;**168**:124–5
- Zhou XH. Primary squamous cell carcinoma of the thyroid. *Eur J Surg Oncol* 2002;**28**:42–5
- Sahoo M, Bal CS, Bhatnagar D. Primary squamous-cell carcinoma of the thyroid gland: new evidence in support of follicular epithelial cell origin. *Diagn Cytopathol* 2002;**27**:227–31
- Lam KY, Lo CY, Liu MC. Primary squamous cell carcinoma of the thyroid gland: an entity with aggressive clinical behaviour and distinctive cytokeratin expression profiles. *Histopathology* 2001;**39**:279–86
- Agrawal R, Tandon V, Agrawal A, Agrawal G, Krishnani N, Mishra SK. Squamous cell carcinoma of thyroid gland. *J Assoc Physicians India* 2001;**49**:279–80
- Jones JM, McCluggage WG, Russell CF. Primary squamous carcinoma of the thyroid. *Ulster Med J* 2000;**69**:58–60
- Cook AM, Vini L, Harmer C. Squamous cell carcinoma of the thyroid: outcome of treatment in 16 patients. *Eur J Surg Oncol* 1999;**25**:606–9
- Kumar PV, Malekhusseini SA, Talei AR. Primary squamous cell carcinoma of the thyroid diagnosed by fine needle aspiration cytology. A report of two cases. *Acta Cytol* 1999;**43**:659–62
- Wan Muhaizan WM, Phang KS, Sharifah NA, al Amin D. Primary squamous cell carcinoma of the thyroid – a case report. *Malays J Pathol* 1998;**20**:109–11
- Chaudhary RK, Barnes EL, Myers EN. Squamous cell carcinoma arising in Hashimoto's thyroiditis. *Head Neck* 1994;**16**:582–5
- Theander C, Löden B, Berglund J, Seidal T. Primary squamous carcinoma of the thyroid – a case report. *J Laryngol Otol* 1993;**107**:1155–8
- Tsuchiya A, Suzuki S, Nomizu T, Yamaki Y, Abe R, Katayama S. Squamous cell carcinoma of the thyroid – a report of three cases. *Jpn J Surg* 1990;**20**:341–5
- Harada T, Katagiri M, Tsukayama C, Higashi Y, Shimaoka K. Squamous cell carcinoma with cyst of the thyroid. *J Surg Oncol* 1989;**42**:136–43
- Simpson WJ, Carruthers J. Squamous cell carcinoma of the thyroid gland. *Am J Surg* 1988;**156**:44–6
- Sarda AK, Bal S, Arunabh, Singh MK, Kapur MM. Squamous cell carcinoma of the thyroid. *J Surg Oncol* 1988;**39**:175–8
- Misonou J, Aizawa M, Kanda M, Uekita Y, Motohara T. Pure squamous cell carcinoma of the thyroid gland – report of an autopsy case and review of the literature. *Jpn J Surg* 1988;**18**:469–74
- Riddle PE, Dincsoy HP. Primary squamous cell carcinoma of the thyroid associated with leukocytosis and hypercalcemia. *Arch Pathol Lab Med* 1987;**111**:373–4
- Huang TY, Lin SG. Primary squamous cell carcinoma of the thyroid. *Indiana Med* 1986;**79**:763–4
- Kapoor VK, Sharma D, Mukhopadhyay AK, Chattopadhyay TK. Primary squamous cell carcinoma of the thyroid gland – a case report. *Jpn J Surg* 1985;**15**:60–2
- Jankowska P, Teoh EM, Fisher C, Rhys Evans P, Nutting CM, Harrington KJ. Isolated intrathyroid metastasis from undifferentiated and squamous carcinoma of the head and neck: the case for surgery and re-irradiation. *Br J Radiol* 2008;**81**:154–61
- Lee MW, Batorov YK, Odashiro AN, Nguyen GK. Solitary metastatic cancer to the thyroid: a report of five cases with fine-needle aspiration cytology. *Cytojournal* 2007;**30**:5
- Ciobanu D, Vulpoi C, Gălușcă B, Florea N, Giușcă SE, Căruntu ID. The value of the immunohistochemical exam in the diagnosis of the secondary malignant tumors to the thyroid gland. *Rom J Morphol Embryol* 2007;**48**:113–19
- Iesalnieks I, Trupka A, Raab M, Glockzin G, Woenckhaus M, Schlitt HJ *et al.* Renal cell carcinoma metastases to the thyroid gland – 8 cases reported. *Thyroid* 2007;**17**:49–52
- Papi G, Fadda G, Corsello SM, Corrado S, Rossi ED, Radighieri E *et al.* Metastases to the thyroid gland: prevalence, clinicopathological aspects and prognosis: a 10-year experience. *Clin Endocrinol (Oxf)* 2007;**66**:565–71
- Bandyopadhyay SK, Bandyopadhyay R, Dutta A. Isolated massive thyroid metastasis in lung cancer. *Singapore Med J* 2006;**47**:324–6
- Karapanagiotou E, Saif MW, Rondoyianni D, Markaki S, Alamarca C, Kiagia M *et al.* Metastatic cervical carcinoma to

- the thyroid gland: a case report and review of the literature. *Yale J Biol Med* 2006;**79**:165–8
- 43 Gerges AS, Shehata SR, Gouda IA. Metastasis to the thyroid gland; unusual site of metastasis. *J Egypt Natl Canc Inst* 2006;**18**:67–72
- 44 Preuss SF, Stenzel M, Hansen T. Metastatic disease of bronchial carcinoma in a thyroid nodule: a case report. *Eur Arch Otorhinolaryngol* 2005;**262**:804–6
- 45 Mirallié E, Rigaud J, Mathonnet M, Gibelin H, Regenet N, Hamy A *et al.* Management and prognosis of metastases to the thyroid gland. *J Am Coll Surg* 2005;**200**:203–7
- 46 Kim TY, Kim WB, Gong G, Hong SJ, Shong YK. Metastasis to the thyroid diagnosed by fine-needle aspiration biopsy. *Clin Endocrinol (Oxf)* 2005;**62**:236–41
- 47 Dequanter D, Lothaire P, Larsimont D, de Saint-Aubain de Somerhausen N, Andry G. Intrathyroid metastasis: 11 cases. *Ann Endocrinol (Paris)* 2004;**65**:205–8
- 48 Wood K, Vini L, Harmer C. Metastases to the thyroid gland: the Royal Marsden experience. *Eur J Surg Oncol* 2004;**30**:583–8
- 49 De Ridder M, Sermeus AB, Urbain D, Storme GA. Metastases to the thyroid gland – a report of six cases. *Eur J Intern Med* 2003;**14**:377–9
- 50 Schwender FT, Wollner I, Kunju LP, Nakhleh RE, Chan KM. Squamous cell carcinoma of the buccal mucosa with metastases to the pericardial cavity, lung and thyroid. *Oral Oncol* 2002;**38**:114–16
- 51 Heffess CS, Wenig BM, Thompson LD. Metastatic renal cell carcinoma to the thyroid gland: a clinicopathologic study of 36 cases. *Cancer* 2002;**95**:1869–78
- 52 Chen H, Nicol TL, Udelsman R. Clinically significant, isolated metastatic disease to the thyroid gland. *World J Surg* 1999;**23**:177–80
- 53 Lam KY, Lo CY. Metastatic tumours of the thyroid gland: a study of 79 cases in Chinese patients. *Arch Pathol Lab Med* 1998;**122**:37–41
- 54 Lin JD, Weng HF, Ho YS. Clinical and pathological characteristics of secondary thyroid cancer. *Thyroid* 1998;**8**:149–53
- 55 Nakhjavani MK, Gharib H, Goellner JR, van Heerden JA. Metastasis to the thyroid gland. A report of 43 cases. *Cancer* 1997;**79**:574–8
- 56 Rosen IB, Walfish PG, Bain J, Bedard YC. Secondary malignancy of the thyroid gland and its management. *Ann Surg Oncol* 1995;**2**:252–6
- 57 Michelow PM, Leiman G. Metastases to the thyroid gland: diagnosis by aspiration cytology. *Diagn Cytopathol* 1995;**13**:209–13
- 58 Smith SA, Gharib H, Goellner JR. Fine-needle aspiration. Usefulness for diagnosis and management of metastatic carcinoma to the thyroid. *Arch Intern Med* 1987;**147**:311–12
- 59 Chacho MS, Greenebaum E, Moussouris HF, Schreiber K, Koss LG. Value of aspiration cytology of the thyroid in metastatic disease. *Acta Cytol* 1987;**31**:705–12
- 60 McCabe DP, Farrar WB, Petkov TM, Finkelmeier W, O'Dwyer P, James A. Clinical and pathologic correlations in disease metastatic to the thyroid gland. *Am J Surg* 1985;**150**:519–23
- 61 Ivy HK. Cancer metastatic to the thyroid: a diagnostic problem. *Mayo Clin Proc* 1984;**59**:856–9
- 62 Vane D, King DR, Boles ET Jr. Secondary thyroid neoplasms in pediatric cancer patients: increased risk with improved survival. *J Pediatr Surg* 1984;**19**:855–60
- 63 Goldberg HM, Harvey P. Squamous-cell cysts of the thyroid with special reference to the aetiology of squamous epithelium in the human thyroid. *Br J Surg* 1956;**43**:565–9
- 64 Kobayashi T, Okamoto S, Maruyama H, Okamura J, Takai S, Mori T. Squamous metaplasia with Hashimoto's thyroiditis presenting as a thyroid nodule. *J Surg Oncol* 1989;**40**:139–42
- 65 Nakhjavani M, Gharib H, Goellner JR, Heerden JA. Direct extension of malignant lesions to the thyroid gland from adjacent organs: report of 17 cases. *Endocr Pract* 1999;**5**:69–71
- 66 Gulisano M, Pirino A, Montella A. Blood and/or lymphatic connection of laryngo-pharynx and thyroid: an anatomic and clinical problem (in Italian). *Boll Soc Ital Biol Sper* 1993;**69**:655–9
- 67 Weber AL, Randolph G, Aksoy FG. The thyroid and parathyroid glands. CT and MR imaging and correlation with pathology and clinical findings. *Radiol Clin North Am* 2000;**38**:1105–29
- 68 Macapinlac HA. FDG-PET in head and neck, and thyroid cancer. *Chang Gung Med J* 2005;**28**:284–95
- 69 DeLellis R. Secondary tumours of the thyroid. In: *Pathology and Genetics of Tumours of Endocrine Organs*. Lyon, France: IARC Press, International Agency for Research on Cancer, 2004;122–3
- 70 Lam KY, Lui MC, Lo CY. Cytokeratin expression profiles in thyroid carcinomas. *Eur J Surg Oncol* 2001;**27**:631–5
- 71 Ordóñez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. *Am J Surg Pathol* 2000;**24**:1217–23
- 72 Agoff SN, Lamps LW, Philip AT, Amin MB, Schmidt RA, True LD *et al.* Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumours. *Mod Pathol* 2000;**13**:238–42
- 73 Pelosi G, Frassetto F, Pasini F, Maisonneuve P, Sonzogni A, Iannucci A *et al.* Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. *Am J Surg Pathol* 2001;**25**:363–72
- 74 Dabbs D. Immunohistology of endocrine tumours. In: *Diagnostic Immunohistochemistry*. Philadelphia: Churchill Livingstone, 2006;**9**:269
- 75 Corrin B, Nicholson AG. Tumours. In: *Pathology of the Lungs*. Edinburgh: Churchill Livingstone, 2005;**12**:675
- 76 Huang TY, Assor D. Primary squamous cell carcinoma of the thyroid gland: a report of four cases. *Am J Clin Pathol* 1971;**55**:93–8
- 77 Kampsen EB, Jager N, Max MH. Squamous cell carcinoma of the thyroid: a report of two cases. *J Surg Oncol* 1977;**9**:567–78
- 78 Shimaoka K, Tsukada Y. Squamous cell carcinomas and adenoid squamous carcinomas originating from the thyroid gland. *Cancer* 1980;**15**:1833–42
- 79 Kukreti SC, Prabhune PV, Upadhyaya GH, Shah HH. Primary squamous cell carcinoma of the thyroid gland. *J Indian Med Assoc* 1972;**16**:287–8
- 80 Harada T, Shimaoka K, Yakumaru K, Ito K. Squamous cell carcinoma of the thyroid gland – transition from adenocarcinoma. *J Surg Oncol* 1982;**19**:36–43
- 81 Harmer C. Thyroid Cancer. In: Horwich A, ed. *Oncology. A Multidisciplinary Textbook*. London: Chapman and Hall, 1995;565–84
- 82 Ericsson M, Biörklund A, Cederquist E, Ingemansson S, Akerman M. Surgical treatment of metastatic disease in the thyroid gland. *J Surg Oncol* 1981;**17**:15–23

Address for correspondence:

Mr Mohammed Iqbal Syed,
Specialist Registrar in Otolaryngology,
Southern General Hospital,
Greater Glasgow and Clyde NHS Trust,
Glasgow G51 4TF,
Scotland, UK

Fax: +44 (0)141 3146616

E-mail: iqbalms@hotmail.com

Mr M I Syed takes responsibility for the integrity of the content of the paper
Competing interests: None declared
